Follow CGSP on Social Media

Listen to the CGSP Podcast

How Does Sinovac’s Efficacy Rate Compare to Other COVID-19 Vaccines?

For the past two weeks, we’ve been discussing the efficacy rates of Chinese vaccines compared to those from other countries and a number of readers have asked for comparative data to measure how jabs from the likes of Sinovac perform against AstraZeneca’s in particular.

Sinovac’s jab that uses inactive agents performs poorly against the more advanced mRNA vaccines from Pfizer, Moderna, and even Russia’s Sputnik V in phase three clinical trials. However, that 50% efficacy rate for Sinovac is only for mild cases. In terms of severe illness or death, it performs at almost 100% which is critical for developing countries because it lowers hospital admission rates.

Lead the Conversation on China

Subscribe Today to Get Full Access to The China-Global South Project

Check Out Everything You'll Get With Your Subscription

The China-Global South Daily Brief delivered to your inbox at 6AM Washington time

Full access to exclusive news and analysis from editors based in the Global South

Transcripts of CGSP’s twice-weekly podcasts

Students and teachers with a valid .edu email address are eligible for a 50% discount off monthly or yearly subscriptions. Email us to receive a discount code.

What is The China-Global South Project?


The China-Global South Project is passionately independent, non-partisan and does not advocate for any country, company or culture.


A carefully curated selection of the day’s most important China-Global South stories. Updated 24 hours a day by human editors. No bots, no algorithms.


Diverse, often unconventional insights from scholars, analysts, journalists and a variety of stakeholders in the China-Global South discourse.


A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.